Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

FG-2216 drug offers new treatment option for kidney disease-related anemia

FG-2216 drug offers new treatment option for kidney disease-related anemia

Overexpression of microRNA 125b can cause leukemia: Research

Overexpression of microRNA 125b can cause leukemia: Research

AMAG updates product label of Feraheme Injection

AMAG updates product label of Feraheme Injection

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Looking back and moving forward: 100 years of Pneumococcal vaccination

Looking back and moving forward: 100 years of Pneumococcal vaccination

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

UMDNJ researchers develop comprehensive strategy for recovery from smoking addiction

Embryonic stem cell research has not made good on taxpayer investment

Embryonic stem cell research has not made good on taxpayer investment

Cord Blood America shares web site post on Thanksgiving Day

Cord Blood America shares web site post on Thanksgiving Day

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex submits NDA for telaprevir for treating hepatitis C

Frequent hemodialysis improves left ventricular mass, physical health than conventional treatment

Frequent hemodialysis improves left ventricular mass, physical health than conventional treatment

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Ligand reverse stock split becomes effective

Ligand reverse stock split becomes effective

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Merck wins third FOSAMAX bellwether trial

Merck wins third FOSAMAX bellwether trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.